[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100484097":3},{"organization":4,"armGroups":7,"interventions":8,"overallOfficials":15,"centralContacts":19,"locations":7,"responsibleParty":27,"collaborators":7,"id":29,"slug":30,"hasResults":31,"nctId":32,"briefTitle":33,"officialTitle":33,"acronym":7,"eligibilityCriteria":34,"healthyVolunteers":31,"sex":35,"minAge":36,"maxAge":7,"enrollmentInfo":7,"targetDuration":7,"studyType":37,"phases":7,"briefSummary":38,"conditions":39,"keywords":41,"overallStatus":47,"whyStopped":7,"lastUpdateSubmitDate":48,"lastUpdatePostDateStruct":49,"startDateStruct":7,"completionDateStruct":7,"leadSponsor":52,"locationsCount":7},{"fullName":5,"class":6},"Novartis","INDUSTRY",null,[9],{"type":10,"name":11,"description":12,"armGroupLabels":7,"otherNames":13},"DRUG","secukinumab","Patients receive secukinumab",[14],"Cosentyx, AIN457",[16],{"name":17,"affiliation":17,"role":18},"Novartis Pharmaceuticals","STUDY_DIRECTOR",[20,25],{"name":21,"role":22,"phone":23,"phoneExt":7,"email":24},"MAP requests are initiated by a licensed physician.https:\u002F\u002F www.novart is.com\u002Fhealthcare-professionals\u002Fmanaged-access-programs","CONTACT","1-888-669-6682","novartis.email@novartis.com",{"name":17,"role":22,"phone":26,"phoneExt":7,"email":7},"+41613241111",{"type":28,"investigatorFullName":7,"investigatorTitle":7,"investigatorAffiliation":7,"oldNameTitle":7,"oldOrganization":7},"SPONSOR","100484097","managed-access-programs-for-ain457-secukinumab-100484097",false,"NCT05583604","Managed Access Programs for AIN457, Secukinumab","Inclusion Criteria:\n\n* An independent request should be received from a licensed physician (in some instances from Health Authorities, Institutions or Governments).\n* The patient has a serious or life-threatening disease or condition and no comparable or satisfactory alternative therapy is available for diagnosis, monitoring or treatment; patient is not medically eligible for available treatment alternatives or has exhausted all available treatment options.\n* The patient is not eligible or able to enroll in a Novartis clinical trial or continue participation in a Novartis clinical trial.\n* There is a potential patient benefit to justify the potential risk of the treatment use, and the potential risk is not unreasonable in the context of the disease or condition to be treated.\n* The patient must meet any other medical criteria established by the medical experts responsible for the product or by the Health Authority in a country (as applicable).\n* Provision of the product will not interfere with the initiation, conduct or completion of a Novartis clinical trial or overall development program.","ALL","12 Years","EXPANDED_ACCESS","The purpose of this registration is to list Managed Access Programs (MAPs) related to AIN457, secukinumab",[40],"Hidradenitis Suppurativa (HS)",[42,43,44,45,11,46],"MAP","Manage Access Program","Hidradenitis suppurativa (HS)","AIN457","Cosentyx","AVAILABLE","2025-12-10",{"date":50,"type":51},"2025-12-18","ACTUAL",{"name":17,"class":6}]